Irreversible electroporation for treatment of colorectal cancer in a porcine model
Research Organization: Mayo Clinic Model: Oncopig Colorectal Cancer
Insights and impact
Get the latest updates on preclinical research. Access our case studies, scientific publications, company milestones, and industry events. Discover how Sus Clinicals is transforming development of breakthrough therapeutics to fight diseases faster.
Publications
Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro
The published work (Segatto et al. 2024 Front. Oncol., 25 February 2024) discusses the development of a novel urothelial carcinoma cell line from Oncopigs®, Sus Clinicals’ genetically modified porcine model. The aim was to create a reliable in vitro model for bladder cancer research. The researchers successfully demonstrated that these Oncopig® bladder cancer cell lines mimic human bladder cancer cell responses to commonly used chemotherapeutic agents (cisplatin, doxorubicin, and gemcitabine).
Read moreEffect of CRISPR Knockout of AXIN1 or ARID1A on Proliferation and Migration of Porcine Hepatocellular Carcinoma
In a groundbreaking study, scientists have used advanced genetic editing techniques (CRISPR) to create customized porcine models for studying liver cancer, specifically hepatocellular carcinoma (HCC). The researchers focused on two key genes, AXIN1 and ARID1A, which are frequently mutated in human liver cancer, and successfully replicated these mutations in pigs. This work lays the foundation for development and utilization of genetically-tailored porcine HCC models for in vivo testing of novel therapeutic approaches in a clinically-relevant large animal model.
Read morePorcine Cancer Models: Potential Tools to Enhance Cancer Drug Trials
The amount of time and money invested into cancer drug research, development, and clinical trials has continually increased over the past few decades. Despite record high cancer drug approval rates, cancer remains a leading cause of death. This suggests the need for more effective tools to help bring novel therapies to clinical practice in a timely manner.
Read moreTranslating Human Cancer Sequences Into Personalized Porcine Cancer Models
The global incidence of cancer is rapidly rising, and despite an improved understanding of cancer molecular biology, immune landscapes, and advancements in cytotoxic, biologic, and immunologic anti-cancer therapeutics, cancer remains a leading cause of death worldwide. The authors explain that by creating pig models that mirror patients' genetic profiles, researchers can improve the predictability of treatment outcomes and accelerate progress in cancer research and treatment.
Read moreOf Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research
Cancer has recently surpassed cardiovascular diseases as the leading cause of death worldwide. The increasing cancer incidence combined with the emergence of improved therapeutic strategies has driven research into fields such as how the immune system Influences cancer development and progression. This article reviews various animal models, and explains the benefits of porcine-based preclinical research.
Read moreKRASG12D And TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus Scrofa Pigs
This article details development of the first large animal model of pancreatic carcinogenesis and may allow for insight into new avenues of translational research not before possible in rodents. By developing a porcine model via the Oncopig platform that closely mimics human pancreatic ductal adenocarcinoma (PDAC), researchers can now explore new treatment modalities, surgical interventions, and radiological techniques that were previously unfeasible in mouse models.
Read moreThe Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery
The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. This article covers how a transgenic pig model can offer a controlled and predictable platform for studying cancer and testing new therapies.
Read moreThe Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform
Cancer is a global epidemic causing more than 8 million annual deaths worldwide. The more than 13 million new cancer diagnoses made each year carry an economic burden of $290B. Cancer is expected to be the second leading cause of death in the United States in 2017. The authors discuss how the Oncopig Cancer Model represents a significant breakthrough in cancer research, providing a powerful and clinically relevant tool to study cancer biology, test therapeutic interventions, and improve patient outcomes in the fight against cancer.
Read moreA Validated, Transitional and Translational Porcine Model of Hepatocellular Carcinoma
This article details a study validating the Oncopig model for hepatocellular carcinoma (HCC). Specifically, the article presents data demonstrating the ability of Oncopig HCC cell lines to recapitulate key features of human HCC, providing validation for the use of the Oncopig platform for human HCC research. This model will enable the testing of different HCC treatment techniques and the evaluation of histologic, radiographic, and pathological responses in a model more similar to human HCC than currently available small animal models.
Read moreOncopig Soft-Tissue Sarcomas Recapitulate Key Transcriptional Features of Human Sarcomas
Human soft-tissue sarcomas (STS) are rare mesenchymal tumors with a 5-year survival rate of 50%, highlighting the need for further STS research. Research has been hampered by limited human sarcoma cell line availability and the large number of STS subtypes, making development of STS cell lines and animal models representative of the diverse human STS subtypes critical. Pigs represent ideal human disease models due to their similar size, anatomy, metabolism, and genetics compared to humans.
Read more
Press releases
Sus Clinicals Appoints Dr. Lawrence Schook to Board of Directors
Sus Clinicals, Inc. announced today that Dr. Lawrence Schook has been elected to the Company’s Board of Directors
Read moreSus Clinicals, Inc. Announces $2 Million Research Grant from the National Institutes of Health
Funding will support breakthrough work against an aggressive form of liver cancer
Read moreSus Clinicals, Inc. Announces Former Jackson Labs Executive Joins the Company as Advisor
Dr. Auro Nair brings over three decades of experience in life sciences and biomedical research
Read moreSus Clinicals, Inc. Announces Formation of Advisory Council
Top experts to advise Company on scientific priorities and innovation strategies
Read moreSus Clinicals Announces Former McKinsey Executive Joins the Company as Advisor
Jeff Sinclair brings 30+ years of experience in strategy, operations and organization design
Read moreSus Clinicals, Inc. Receives Clearance from the U.S. Food & Drug Administration
Grant of Enforcement Discretion Supports Commercial Launch
Read moreSus Clinicals, Inc. Announces New License Agreement for Advancement in Cancer-Related Research
Patent-Pending Technology from the University of Illinois Leverages Large Animal Model to Accelerate Pre-Clinical Testing for Cancer Therapies
Read more